- ARCA biopharma (NASDAQ:ABIO) has submitted a Patent Cooperation Treaty (PCT) patent application for the use of the company’s developmental drug rNAPc2 to treat patients hospitalized with COVID-19.
- rNAPc2 is a small recombinant protein being developed as a potential treatment for serious viral infections, initially focusing on COVID-19.
- Shares up nearly 2% premarket.
ARCA Biopharma submits PCT patent application for rNAPc2 in COVID-19
Recommended For You
More Trending News
About ABIO Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| ABIO | - | - |
| ARCA biopharma, Inc. | ||